Year: 2024
Type: article
Study design: Observational Study
Abstract: A summary of the reports is presented, which are included in the database of the World Health Organization's international drug monitoring program as of March 23, 2022 on the use of rivaroxaban, recommended for the use of the prevention of thrombotic complications and the most often combined drug found in clinical practice. Cases of drug interaction were analyzed and safety analysis of combination therapy was carried out. This material is presented for doctors, researchers, health regulators.
Source: Russian Medicine
Author: Andrey Kondrakhin
Institution: Pirogov Russian National Research Medical University
Language: English
Subfield: Toxicology
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W4401864166